AT
IONS icon

American Trust’s Ionis Pharmaceuticals IONS Stock Holding History

American Trust’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,970
Closed -$603K – 465
2022
Q4 		$603K Buy
+15,970
New +$672K 0.06% 186

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

American Trust's IONS Position: Q1 2023 in Review

American Trust sold out of Ionis Pharmaceuticals (IONS) in Q1 2023, closing a stake of 15,970 shares — an estimated $603K sold.

American Trust first reported a position in IONS in Q4 2022 and held it in 1 quarter. The position peaked at $603K in Q4 2022. 313 funds tracked by Wall St. Rank hold IONS as of Q1 2023.

  • American Trust reported no remaining Ionis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • American Trust sold 15,970 Ionis Pharmaceuticals shares in Q1 2023, an estimated $603K.
  • American Trust first reported a position in Ionis Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • American Trust's Ionis Pharmaceuticals position peaked at $603K in Q4 2022.
  • 313 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2023.

Based on American Trust's 13F filing for Q1 2023, filed 22 May 2023.